Prostate Cancer | Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Prostate Cancer

published 4 months ago by Dr Neil Love

Featuring perspectives from Drs Tanya B Dorff, Fred Saad, A Oliver Sartor and Matthew R Smith, including the following topics: Introduction (0:00) Case: A man in his late 80s with metastatic hormone-sensitive prostate cancer (HSPC) (4:16) LHRH agonists versus antagonists; injections versus oral agents (12:29) Case presentations: Patients in their late 60s with metastatic HSPC (15:37) Management of nonmetastatic castration-resistant prostate cancer (CRPC) (25:22) Case: A man in his late 80s with nonmetastatic HSPC (29:31) Case: A man in his late 60s with nonmetastatic PC (39:02) Case: A man in his early 60s with metastatic CRPC with a germline BRCA2 mutation (42:46) Case: A man in his late 70s with metastatic CRPC with a somatic BRCA2 mutation (47:52) Case: A man in his early 70s with metastatic CRPC with a germline BRCA2 mutation (51:05) Case: A man in his early 60s with metastatic CRPC with a BRCA2 mutation who received olaparib (56:40) Case: A man in his early 70s with HSPC (1:00:28) Case: A man in his late 60s with metastatic HSPC (1:06:35) Immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy in metastatic CRPC (1:08:46) Clinical data from the Phase III ACIS study assessing apalutamide with abiraterone acetate and prednisone in chemotherapy-naïve metastatic CRPC (1:12:52) Case: A man in his late 80s with metastatic CRPC (1:15:42) Case: A man in his early 90s with metastatic CRPC (1:25:32) CME information and select publications

more episodes from Research To Practice | Oncology Videos